Statement attributable to:
Robert McLean, MD, FACP
President, ƹϵεapp
Washington, DC (May 9, 2019) —The ƹϵεapp (ACP) is encouraged by the final rule announced by the Trump Administration to require pharmaceutical manufacturers to disclose the cost of drugs in television advertisements. ACP believes that this is a promising step in improving transparency in prescription drug pricing. Prescription medications are only as effective as a patient’s ability to access and adhere to treatment as prescribed.
Statement attributable to:
Robert McLean, MD, FACP
President, ƹϵεapp
Washington, DC (May 2, 2019) —ƹϵεapp (ACP) is encouraged by the passage of the Climate Action Now Act in the U.S. House of Representatives, which directs the U.S. to uphold its commitment to the Paris Agreement on Climate Change. ACP is deeply concerned about the negative impact that climate change is having on public health and patients, and that these effects will worsen without immediate action.
Statement attributable to:
Robert McLean, MD, FACP
President, ƹϵεapp
Washington, D.C. April 16, 2019 -- The ƹϵεapp (ACP) published a paper today in the Annals of Internal Medicine that examines ways to improve the Affordable Care Act (ACA). provides a set of recommendations to strengthen the ACA and lay the foundation for health care reforms that will lead to universal coverage for all Americans.
ACP Innovation Challenge is part of ACP's support of innovation in medicine
Philadelphia, April 13, 2019 – Jonathan Dau, MD, won the ACP Innovation Challenge grand prize today during Internal Medicine Meeting 2019, the annual scientific meeting of the ƹϵεapp (ACP). ACP awarded $20,000 to Dr. Dau, an internal medicine resident at The University of Texas Health Science Center at Houston, for “Prescription (Rx) for Produce: A Grassroots Medicine, Farm‐to‐Hospital Initiative.”
